Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. .
ADMA Biologics, Inc.February 26, 2021 GMT
Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae
to Bridge Vaccination and Seroconversion Across Multiple Serotypes
By Using as an Add-On with a Vaccine or Antibiotics, This Therapeutic Strategy has the Potential to Improve S. Pneumoniae
-Related Hospital Clinical Outcomes
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 26, 2021 (GLOBE NEWSWIRE) ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the presentation of a late-breaking poster at the 2021 American Academy of Allergy, Asthma & Immunology Conference (“AAAAI”) Virtu